Literature DB >> 24553576

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Andrés P Varani1, Ester Aso, Lirane Machado Moutinho, Rafael Maldonado, Graciela N Balerio.   

Abstract

RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence.
OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice.
RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations.
CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553576     DOI: 10.1007/s00213-014-3469-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  73 in total

Review 1.  Drug addiction, dysregulation of reward, and allostasis.

Authors:  G F Koob; M Le Moal
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

2.  Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.

Authors:  G Colombo; R Agabio; M A Carai; C Lobina; M Pani; R Reali; G Addolorato; G L Gessa
Journal:  Alcohol Clin Exp Res       Date:  2000-01       Impact factor: 3.455

3.  Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects.

Authors:  S S Watkins; L Stinus; G F Koob; A Markou
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

4.  Effects of smoking/nicotine on anxiety, heart rate, and lateralization of EEG during a stressful movie.

Authors:  D G Gilbert; J H Robinson; C L Chamberlin; C D Spielberger
Journal:  Psychophysiology       Date:  1989-05       Impact factor: 4.016

5.  Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

Authors:  A Castañé; E Valjent; C Ledent; M Parmentier; R Maldonado; O Valverde
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

6.  Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells.

Authors:  A R Tomé; V Izaguirre; L M Rosário; V Ceña; C González-García
Journal:  Brain Res       Date:  2001-06-08       Impact factor: 3.252

7.  Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.

Authors:  Tomohisa Mori; Sachiko Komiya; Naoki Uzawa; Koichi Inoue; Toshimasa Itoh; Shiyou Aoki; Masahiro Shibasaki; Tsutomu Suzuki
Journal:  Eur J Pharmacol       Date:  2013-05-23       Impact factor: 4.432

8.  Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.

Authors:  Paola Fadda; Maria Scherma; Alessandra Fresu; Maria Collu; Walter Fratta
Journal:  Synapse       Date:  2003-10       Impact factor: 2.562

9.  Combined exposure to nicotine and ethanol in adolescent mice differentially affects anxiety levels during exposure, short-term, and long-term withdrawal.

Authors:  Yael Abreu-Villaça; Fernanda Nunes; Fabíola do E Queiroz-Gomes; Alex C Manhães; Cláudio C Filgueiras
Journal:  Neuropsychopharmacology       Date:  2007-04-25       Impact factor: 7.853

Review 10.  The scientific case that nicotine is addictive.

Authors:  I P Stolerman; M J Jarvis
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

View more
  3 in total

Review 1.  The GABAB Receptor-Structure, Ligand Binding and Drug Development.

Authors:  Linn Samira Mari Evenseth; Mari Gabrielsen; Ingebrigt Sylte
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

2.  α-Conotoxin TxIB: A Uniquely Selective Ligand for α6/α3β2β3 Nicotinic Acetylcholine Receptor Attenuates Nicotine-Induced Conditioned Place Preference in Mice.

Authors:  Shen You; Xiaodan Li; Jian Xiong; Xiaoyu Zhu; Dongting Zhangsun; Xiaopeng Zhu; Sulan Luo
Journal:  Mar Drugs       Date:  2019-08-22       Impact factor: 5.118

3.  Preventive effect of central administration of venlafaxine on morphine physical dependence, nociception, and blood cortisol level in rat.

Authors:  Majid Motaghinejad; Andia Ebrahimzadeh; Behnaz Shabab
Journal:  Int J Prev Med       Date:  2014-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.